Cytokinetics Wins UK Approval for MYQORZO in oHCM
SOUTH SAN FRANCISCO, Calif., July 30, 2026 Cytokinetics, Incorporated has achieved a major regulatory and market access milestone for...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., July 30, 2026 Cytokinetics, Incorporated has achieved a major regulatory and market access milestone for...
THOUSAND OAKS, Calif., July 29, 2026 Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP)...
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
